Niraparib Tosylate Monohydrate

(nih-RA-puh-rib TOH-suh-layt MAH-noh-HY-drayt)

This page contains brief information about niraparib tosylate monohydrate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Zejula

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Niraparib tosylate monohydrate is approved to treat:

Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used as maintenance therapy in patients with recurrent disease who are having a complete or partial response to platinum chemotherapy.

Niraparib tosylate monohydrate is also being studied in the treatment of other types of cancer.

More About Niraparib Tosylate Monohydrate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Niraparib Tosylate Monohydrate - A lay language summary of important information about this drug that may include the following:

warnings about this drug,
what this drug is used for and how it is used,
what you should tell your doctor before using this drug,
what you should know about this drug before using it,
other drugs that may interact with this drug, and
possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Cancer Therapies

FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Niraparib Tosylate Monohydrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.